ArticlePloS one2025
In silico identification, high yielding isolation and in vitro validation of 6β-cinnamoyl-7β -hydroxyvouacapen - 5α - ol as a Wnt/β-catenin pathway targeted anti-cancer secondary metabolite of Caesalpinia pulcherrima.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wnt/β-catenin signaling pathway is frequently dysregulated in cancer stem cells (CSCs), a sub population of cancer cell mass that drives tumor proliferation, metastasis, recurrence, and chemoresistance. Despite its therapeutic significance, no clinically approved drugs specifically target this pathway. In the present study, secondary metabolites of the medicinal plant Caesalpinia pulcherrima was computationally screened by molecular docking, dynamics simulation and Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) based free energy calculations to identify potential inhibitors of β-catenin-Tcf/Lef interaction, a key downstream event essential for Wnt/β-catenin signaling. Diterpene metabolite 6β-Cinnamoyl-7β-hydroxyvouacapen-5α-ol (6βCHV) was identified as a potent inhibitor of the pathway along with four previously reported Wnt/β-catenin pathway inhibitors. To validate the results, bioactivity-guided isolation of major active compound was performed using NTERA-2 cells as a cancer stem cell (CSC) model. The isolated compound was spectroscopically characterized and confirmed to be 6βCHV. Anti-proliferative activity assays revealed that 6βCHV suppressed proliferation of breast cancer stem cells (bCSCs) (IC₅₀ = 49.18 µM), NTERA-2 cells (IC₅₀ = 8.92 µM), and highly Wnt-dependent cancer types, including gastric adenocarcinoma (IC₅₀ = 1.90 µM), hepatocellular carcinoma (IC₅₀ = 5.96 µM), and ovarian carcinoma (IC₅₀ = 7.66 µM). 6βCHV upregulated the tumor suppressor gene, p53 while downregulating Wnt target genes, Cyclin D1 and CD44 leading to apoptosis in bCSCs as confirmed by Caspase 3/7 activation. These findings establish 6βCHV as the principal anticancer compound in C. pulcherrima, exerting its effects, at least in part, through Wnt/β-catenin pathway inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.